Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy

Y. Yu, Yohan Suryo Rahmanto, D. R. Richardson

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND PURPOSE Our previous studies demonstrated that a thiosemicarbazone iron chelator (di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone; Dp44mT) possesses potent and selective anti-cancer activity but led to cardiotoxicity at non-optimal doses. In this study, we examined the in vivo anti-tumour efficacy and tolerability of a new-generation 2-benzoylpyridine thiosemicarbazone iron chelator (2-benzoylpyridine-4,4- dimethyl-3-thiosemicarbazone; Bp44mT) administered via the oral or i.v. routes. EXPERIMENTAL APPROACH BpT chelators were tested in vitro against human lung cancer cells (DMS-53) and in vivo in DMS-53 tumour xenografts in mice. The toxicity of Bp44mT in vivo and its effects on the expression of iron-regulated molecules involved in growth and cell cycle control were investigated. KEY RESULTS Administration of Bp44mT by either route resulted in marked dose-dependent inhibition of tumour growth. When administered at 50 mg·kg -1 via oral gavage three times per week for 23 days, the net xenograft growth was inhibited by 75%, compared with vehicle-treated mice. Toxicological examination showed reversible alterations including slight reduction of RBC count, with a decrease of liver and splenic iron levels, which confirmed iron chelation in vivo. Importantly, in contrast to Dp44mT, the chelator-treated mice did not show cardiac histological abnormalities. There was also no significant weight loss in mice, suggesting oral administration of Bp44mT was well tolerated. CONCLUSIONS AND IMPLICATIONS This is the first study to show that Bp44mT can be given orally with potent anti-tumour efficacy. Oral administration of a novel and effective chemotherapeutic agent provides the benefits of convenience for chronic dosing regimens.

Original languageEnglish (US)
Pages (from-to)148-166
Number of pages19
JournalBritish Journal of Pharmacology
Volume165
Issue number1
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Thiosemicarbazones
Chelating Agents
Iron
Neoplasms
Heterografts
Oral Administration
Growth
Cell Cycle Checkpoints
Toxicology
2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone
Weight Loss
Lung Neoplasms
Liver
di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone

Keywords

  • anti-tumour chemotherapeutic
  • iron chelator
  • oral activity

ASJC Scopus subject areas

  • Pharmacology

Cite this

Bp44mT : An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. / Yu, Y.; Suryo Rahmanto, Yohan; Richardson, D. R.

In: British Journal of Pharmacology, Vol. 165, No. 1, 01.01.2012, p. 148-166.

Research output: Contribution to journalArticle

Yu, Y. ; Suryo Rahmanto, Yohan ; Richardson, D. R. / Bp44mT : An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. In: British Journal of Pharmacology. 2012 ; Vol. 165, No. 1. pp. 148-166.
@article{7ad8ad0e3d804952bbee4809b3c16c12,
title = "Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy",
abstract = "BACKGROUND AND PURPOSE Our previous studies demonstrated that a thiosemicarbazone iron chelator (di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone; Dp44mT) possesses potent and selective anti-cancer activity but led to cardiotoxicity at non-optimal doses. In this study, we examined the in vivo anti-tumour efficacy and tolerability of a new-generation 2-benzoylpyridine thiosemicarbazone iron chelator (2-benzoylpyridine-4,4- dimethyl-3-thiosemicarbazone; Bp44mT) administered via the oral or i.v. routes. EXPERIMENTAL APPROACH BpT chelators were tested in vitro against human lung cancer cells (DMS-53) and in vivo in DMS-53 tumour xenografts in mice. The toxicity of Bp44mT in vivo and its effects on the expression of iron-regulated molecules involved in growth and cell cycle control were investigated. KEY RESULTS Administration of Bp44mT by either route resulted in marked dose-dependent inhibition of tumour growth. When administered at 50 mg·kg -1 via oral gavage three times per week for 23 days, the net xenograft growth was inhibited by 75{\%}, compared with vehicle-treated mice. Toxicological examination showed reversible alterations including slight reduction of RBC count, with a decrease of liver and splenic iron levels, which confirmed iron chelation in vivo. Importantly, in contrast to Dp44mT, the chelator-treated mice did not show cardiac histological abnormalities. There was also no significant weight loss in mice, suggesting oral administration of Bp44mT was well tolerated. CONCLUSIONS AND IMPLICATIONS This is the first study to show that Bp44mT can be given orally with potent anti-tumour efficacy. Oral administration of a novel and effective chemotherapeutic agent provides the benefits of convenience for chronic dosing regimens.",
keywords = "anti-tumour chemotherapeutic, iron chelator, oral activity",
author = "Y. Yu and {Suryo Rahmanto}, Yohan and Richardson, {D. R.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1476-5381.2011.01526.x",
language = "English (US)",
volume = "165",
pages = "148--166",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Bp44mT

T2 - An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy

AU - Yu, Y.

AU - Suryo Rahmanto, Yohan

AU - Richardson, D. R.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - BACKGROUND AND PURPOSE Our previous studies demonstrated that a thiosemicarbazone iron chelator (di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone; Dp44mT) possesses potent and selective anti-cancer activity but led to cardiotoxicity at non-optimal doses. In this study, we examined the in vivo anti-tumour efficacy and tolerability of a new-generation 2-benzoylpyridine thiosemicarbazone iron chelator (2-benzoylpyridine-4,4- dimethyl-3-thiosemicarbazone; Bp44mT) administered via the oral or i.v. routes. EXPERIMENTAL APPROACH BpT chelators were tested in vitro against human lung cancer cells (DMS-53) and in vivo in DMS-53 tumour xenografts in mice. The toxicity of Bp44mT in vivo and its effects on the expression of iron-regulated molecules involved in growth and cell cycle control were investigated. KEY RESULTS Administration of Bp44mT by either route resulted in marked dose-dependent inhibition of tumour growth. When administered at 50 mg·kg -1 via oral gavage three times per week for 23 days, the net xenograft growth was inhibited by 75%, compared with vehicle-treated mice. Toxicological examination showed reversible alterations including slight reduction of RBC count, with a decrease of liver and splenic iron levels, which confirmed iron chelation in vivo. Importantly, in contrast to Dp44mT, the chelator-treated mice did not show cardiac histological abnormalities. There was also no significant weight loss in mice, suggesting oral administration of Bp44mT was well tolerated. CONCLUSIONS AND IMPLICATIONS This is the first study to show that Bp44mT can be given orally with potent anti-tumour efficacy. Oral administration of a novel and effective chemotherapeutic agent provides the benefits of convenience for chronic dosing regimens.

AB - BACKGROUND AND PURPOSE Our previous studies demonstrated that a thiosemicarbazone iron chelator (di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone; Dp44mT) possesses potent and selective anti-cancer activity but led to cardiotoxicity at non-optimal doses. In this study, we examined the in vivo anti-tumour efficacy and tolerability of a new-generation 2-benzoylpyridine thiosemicarbazone iron chelator (2-benzoylpyridine-4,4- dimethyl-3-thiosemicarbazone; Bp44mT) administered via the oral or i.v. routes. EXPERIMENTAL APPROACH BpT chelators were tested in vitro against human lung cancer cells (DMS-53) and in vivo in DMS-53 tumour xenografts in mice. The toxicity of Bp44mT in vivo and its effects on the expression of iron-regulated molecules involved in growth and cell cycle control were investigated. KEY RESULTS Administration of Bp44mT by either route resulted in marked dose-dependent inhibition of tumour growth. When administered at 50 mg·kg -1 via oral gavage three times per week for 23 days, the net xenograft growth was inhibited by 75%, compared with vehicle-treated mice. Toxicological examination showed reversible alterations including slight reduction of RBC count, with a decrease of liver and splenic iron levels, which confirmed iron chelation in vivo. Importantly, in contrast to Dp44mT, the chelator-treated mice did not show cardiac histological abnormalities. There was also no significant weight loss in mice, suggesting oral administration of Bp44mT was well tolerated. CONCLUSIONS AND IMPLICATIONS This is the first study to show that Bp44mT can be given orally with potent anti-tumour efficacy. Oral administration of a novel and effective chemotherapeutic agent provides the benefits of convenience for chronic dosing regimens.

KW - anti-tumour chemotherapeutic

KW - iron chelator

KW - oral activity

UR - http://www.scopus.com/inward/record.url?scp=80053926659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053926659&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01526.x

DO - 10.1111/j.1476-5381.2011.01526.x

M3 - Article

C2 - 21658021

AN - SCOPUS:80053926659

VL - 165

SP - 148

EP - 166

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -